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Background
The design of antibody derivatives with higher tumour cell
selectivity is hoped to improve cancer immunotherapy and
to decrease side effects. One promising molecular format
that we have developed is the triple body. A triple body
allows for selective lysis based on its ‘dual targeting’ capa-
city. The triple body format consists of three linked single
chain variable fragments (scFv) with the two distal scFvs
targeting different antigens on the tumour cell surface. The
central scFv triggers an available immune effector cell for
redirected lysis of the tumour cell. For the triple body anti
[HLA-DR-CD16-CD19], it was previously shown that dou-
ble-positive target cells were preferentially eliminated by
NK cells versus single-positive targets. In the present study,
a triple body designated a[19-3-19] with specificity for
CD19 and CD3ε was constructed, produced and tested to
determine whether a triple body could also recruit effector
T cells as this has not previously been demonstrated.
Materials and methods
For the construction and production of a[19-3-19],
standard molecular biology procedures were employed.
Flow cytometry was used to determine the specific bind-
ing behaviour of a[19-3-19] and to characterise various
T cell subsets. The cytotoxic potential of a[19-3-19] was
evaluated in redirected lysis assays using variable effec-
tor-to-target ratios against the B cell lines SEM, Nalm-6,
Raji, Namalwa and ARH77 as well as cells from an
MPAL patient.
Results
We show that the triple body a[19-3-19] binds to
CD19-positive cells and primary T cells. When tested in
cytotoxicity assays, the triple body mediated up to 95%
specific lysis of CD19-positive tumour cells from estab-
lished B-ALL cell lines as well as against cells isolated
from primary patient material using pre-stimulated allo-
geneic effector T cells in vitro after 3 hours incubation.
At effector-to-target ratios of 1:10, a[19-3-19] still led to
the depletion of approximately 60% of CD19-positive
cells. Furthermore, the a[19-3-19] triplebody activated
resting T cells from healthy unrelated donors and
induced the specific lysis of autologous CD19-positive
cells.
Conclusion
These results show that the molecular format of the tri-
ple body using CD3ε as a T cell trigger is also suitable
for the specific killing of leukaemia cells. In addition,
the ‘dual-targeting’ capacity of triple bodies could make
these molecules potentially powerful therapeutic agents
for the selective and efficient elimination of leukaemia
cells while sparing normal healthy cells.
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